Get the Stockscreener App
62.90
0.65%
-0.41
Cidara Therapeutics Inc stock is traded at $62.90, with a volume of 302.04K.
It is down -0.65% in the last 24 hours and up +28.29% over the past month.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
See More
Previous Close:
$63.31
Open:
$62.18
24h Volume:
302.04K
Relative Volume:
0.47
Market Cap:
$1.34B
Revenue:
$56.54M
Net Income/Loss:
$-30.70M
P/E Ratio:
-161.28
EPS:
-0.39
Net Cash Flow:
$-31.05M
1W Performance:
+1.70%
1M Performance:
+28.29%
6M Performance:
+238.63%
1Y Performance:
+387.98%
1-Day Range:
$61.90
$64.25
1-Week Range:
$60.71
$64.95
52-Week Range:
$10.14
$66.94
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Name
Cidara Therapeutics Inc
Sector
Industry
Phone
858-752-6170
Address
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Compare CDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
62.90 | 1.40B | 56.54M | -30.70M | -31.05M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Mar-12-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-27-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Nov-08-24 | Initiated | Guggenheim | Buy |
| Aug-14-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-03-21 | Resumed | H.C. Wainwright | Buy |
| Sep-22-21 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-04-21 | Initiated | Aegis Capital | Buy |
| Sep-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Jul-26-18 | Initiated | Citigroup | Buy |
| Apr-21-17 | Initiated | Raymond James | Strong Buy |
| Apr-17-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-11-17 | Resumed | Wedbush | Outperform |
| Feb-22-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-17 | Upgrade | WBB Securities | Sell → Hold |
| Dec-21-16 | Resumed | Leerink Partners | Outperform |
| Dec-19-16 | Initiated | H.C. Wainwright | Buy |
| Sep-23-16 | Downgrade | WBB Securities | Hold → Sell |
| Oct-09-15 | Upgrade | WBB Securities | Sell → Hold |
| May-11-15 | Initiated | Jefferies | Buy |
| May-11-15 | Initiated | Leerink Partners | Outperform |
| May-11-15 | Initiated | Needham | Buy |
| May-11-15 | Initiated | Wedbush | Outperform |
| Apr-23-15 | Initiated | WBB Securities | Sell |
View All
Cidara Therapeutics Inc Stock (CDTX) Latest News
Will Cidara Therapeutics Inc. Bounce From 52 Week LowTriple Digit Growth Focused Trade Plan Reviewed - metal.it
Moving Average Crossover Confirms Uptrend in Cidara Therapeutics Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
How Cidara Therapeutics Inc. stock performs during market volatilityHigh Win Rate Trading Opportunities Detected - beatles.ru
Can trapped investors hope for a rebound in Cidara Therapeutics Inc.Real-Time Trade Insights Spark Market Reactions - metal.it
Will Cidara Therapeutics Inc. stock split in the near futureInvestment Strategy With Predictable Gains Outlined - metal.it
Candidemia Market Analysis and Forecast Report 2025-2035 Featuring Pfizer, Cidara Therapeutics, Scynexis, Merck, Basilea Pharmaceutica, Lupin Pharmaceuticals, Astellas PharmaResearchAndMarkets.com - FinancialContent
Why Cidara Therapeutics Inc. stock attracts strong analyst attentionBuy Signal Based on Chart Analysis Confirmed - metal.it
Why is Cidara Therapeutics Inc. stock attracting strong analyst attentionFree Market Volatility Navigation Tips - jammulinksnews.com
What is Cidara Therapeutics Inc. company’s growth strategySwing Trade Updates To Watch Now - jammulinksnews.com
What institutional investors are buying Cidara Therapeutics Inc. stockBuild wealth with reliable stock picks - jammulinksnews.com
What are analysts’ price targets for Cidara Therapeutics Inc. in the next 12 monthsUnlock powerful stock screening for profits - jammulinksnews.com
What makes Cidara Therapeutics Inc. stock price move sharplyOutstanding risk-reward balance - jammulinksnews.com
Is Cidara Therapeutics Inc. stock overvalued or undervaluedUnlock expert stock analysis and alerts - jammulinksnews.com
Why Cidara Therapeutics Inc. stock attracts strong analyst attention Fundamental + Technical Combined Watchlist - metal.it
What is the dividend policy of Cidara Therapeutics Inc. stockInvest confidently with real-time data analysis - jammulinksnews.com
How strong is Cidara Therapeutics Inc. company’s balance sheetTrack emerging stocks with high growth potential - jammulinksnews.com
Published on: 2025-07-28 06:14:55 - jammulinksnews.com
How does Cidara Therapeutics Inc. compare to its industry peersDiscover breakthrough trading strategies - jammulinksnews.com
What are Cidara Therapeutics Inc. company’s key revenue driversRapid capital growth - jammulinksnews.com
Published on: 2025-07-27 22:06:43 - jammulinksnews.com
Should I hold or sell Cidara Therapeutics Inc. stock in 2025Get real-time alerts on top-performing stocks - jammulinksnews.com
Cidara Therapeutics Inc. Stock Analysis and ForecastHigh-profit stock alerts - PrintWeekIndia
What drives Cidara Therapeutics Inc. stock priceTriple-digit growth rates - PrintWeekIndia
Will Cidara Therapeutics Inc. stock benefit from interest rate changesRapid market gains - jammulinksnews.com
What analysts say about Cidara Therapeutics Inc. stockRapid market gains - PrintWeekIndia
Cidara Therapeutics to Report Second Quarter 2025 Financial - GlobeNewswire
Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 - 富途牛牛
Cidara Therapeutics Sets Q2 Earnings Date: Key Updates on DFC Immunotherapy Platform Expected - Stock Titan
Is Cidara Therapeutics Inc. a good long term investmentMarket-beating returns - Autocar Professional
Cidara more than doubles on phase 2 flu preventative data - MSN
Cidara Therapeutics Inc Stock (CDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):